On October 15, 2026, Du Kai, Executive Vice President and Chief Commercial Officer (EVP & CCO) of Gan & Lee Pharmaceuticals ("Gan & Lee," stock code: 603087.SH), alongside the company's international business team, held a meeting with Türkiye's Deputy Minister of Health, Assoc. Prof. Şuayıp Birinci, and other officials in Ankara. The talks centered on cooperation on innovative medicines, reliable long-term insulin supply, and the development of local manufacturing capabilities. The meeting aimed to advance Gan & Lee's long-term strategic cooperation in Türkiye, expand access to therapies for metabolic diseases, and bolster supply security.

According to the International Diabetes Federation (IDF), Türkiye has substantial demand for diabetes medicines. In 2024, approximately 9.6 million adults aged 20–79 in Türkiye were living with diabetes, representing an age-standardized prevalence of 16.5%. Both figures were the highest in the IDF European Region.¹ According to World Obesity data, the prevalence of overweight and obesity among adults in Türkiye in 2025 stood at 38.4% and 21.4%, respectively.² By 2030, the combined number of adults living with overweight or obesity is projected to reach approximately 47.44 million.³ The large population living with diabetes, alongside the considerable burden of overweight and obesity, underscores the need for chronic disease management and reliable, long-term access to medications. Ensuring a continuous insulin supply and developing local manufacturing capabilities are therefore important steps toward improving treatment access.

During the meeting, the Gan & Lee delegation presented the company's pipeline, global operations, and manufacturing capabilities. The presentation highlighted preparations for commercialization following EU approvals of its insulin products, recent progress in insulin partnerships and product registrations in Türkiye, and the company's production capacity. It also demonstrated Gan & Lee's large-scale, standardized manufacturing systems and its ability to provide a consistent supply of high-quality insulin to global markets.

Gan & Lee places great importance on the Turkish market and closely monitors local diabetes care needs and healthcare system development. The company secured approval for its insulin glargine injection in Türkiye in 2016. Committed to long-term cooperation, Gan & Lee has actively supported the development of local insulin manufacturing capabilities and has completed technology transfer under its partnership for local insulin glargine production. During the meeting, the delegation reaffirmed its commitment to introducing additional pipeline candidates and innovative medicines to Türkiye and further deepening cooperation to benefit local patients.

Deputy Minister of Health Assoc. Prof. Şuayıp Birinci and the participating officials expressed strong interest in and appreciation for Gan & Lee's insulin development pipeline, product quality, preparations for EU commercialization, and global supply capabilities. Both sides held detailed discussions on cooperation in new medicines and pharmaceutical supply security, laying the groundwork for further project coordination and greater mutual trust between the company and the ministry.

The year 2026 marks the 55th anniversary of diplomatic relations between China and Türkiye. This meeting further strengthened communication and mutual trust between Gan & Lee and Türkiye's Ministry of Health, supporting coordinated efforts to ensure a stable supply of medicines and deepen industry cooperation. Through high-quality biologics, Gan & Lee aims to expand treatment access, better meet patients' long-term medication needs, and contribute to global public health.

Note: In this article, body mass index (BMI) is calculated as weight in kilograms divided by height in meters squared: BMI = weight (kg) / height (m)². Overweight is defined as 25 ≤ BMI < 30 kg/m², obesity as BMI ≥ 30 kg/m², and overweight and obesity combined as BMI ≥ 25 kg/m².

References

1.International Diabetes Federation. IDF Diabetes      Atlas, 11th Edition, 2025.

2.World Obesity Federation. Türkiye:      Prevalence Data.

3.World Obesity Federation. World Obesity      Publications: Türkiye Projections.

About Gan & Lee

Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company and the first in China to master industrial-scale manufacturing technologies for recombinant insulin analogs. The Company has established a comprehensive insulin research and development pipeline.

Currently, Gan & Lee offers six core insulin products, including five insulin analogs: insulin glargine injection (Basalin^®; EU brand name Ondibta^®), insulin lispro injection (Prandilin^®; EU brand name: Bysumlog^®), insulin aspart injection (Rapilin^®; EU brand name: Dazparda^®), premixed insulin lispro protamine suspension injection (25R) (Prandilin^®25), and insulin aspart 30 injection (Rapilin^®30); as well as one human insulin product, premixed human insulin protamine suspension injection (30R) (Similin^®30), together with related delivery devices. These products cover the long-acting, rapid-acting, and premixed insulins.

In China's second round of national volume-based procurement for insulin, Gan & Lee ranked first among selected companies by contracted volume for insulin analogs, further strengthening its domestic market position. In parallel, the Company continues to advance its international expansion.  Insulin glargine injection, insulin lispro injection, and insulin aspart injection have all received marketing authorization from the European Commission (EC). Gan & Lee is steadily progressing toward its goal of becoming a key global participant in the field of metabolic diseases.

Looking forward, Gan & Lee is committed to achieving comprehensive coverage across the diabetes treatment landscape and further enhancing its competitive position in this therapeutic area. The Company will also actively pursue the development of innovative chemical drugs and biologics, with a strategic focus on metabolic diseases, cardiovascular diseases, and other therapeutic areas.